Mitsubishi Tanabe Pharma America to Showcase Groundbreaking ALS Research at NEALS 2025 Mitsubishi Tanabe Pharma America reveals eight innovative research presentations on ALS at the NEALS 2025 Annual Meeting, highlighting advancements in care.

Mitsubishi Tanabe Pharma America to Showcase Groundbreaking ALS Research at NEALS 2025 #United_States #ALS_Research #Clearwater #Mitsubishi_Tanabe #RADICAVA_ORS

Long-Term Analysis Shows Benefits of RADICAVA ORS in ALS Patients Mitsubishi Tanabe Pharma America has published a significant analysis showing that RADICAVA ORS treatment may slow functional decline and improve survival for ALS patients.

Long-Term Analysis Shows Benefits of RADICAVA ORS in ALS Patients #USA #Jersey_City #ALS #Mitsubishi_Tanabe #RADICAVA_ORS

Mitsubishi Tanabe Pharma Celebrates Three Years of RADICAVA ORS® in the U.S. for ALS Patients Mitsubishi Tanabe Pharma America celebrates the three-year anniversary of RADICAVA ORS® in the U.S., providing ALS treatment for over 13,500 patients.

Mitsubishi Tanabe Pharma Celebrates Three Years of RADICAVA ORS® in the U.S. for ALS Patients #United_States #Jersey_City #Mitsubishi_Tanabe #ALS_Treatment #RADICAVA_ORS

Mitsubishi Tanabe Pharma America to Present ALS Research at MDA 2025 Conference Mitsubishi Tanabe Pharma America is set to unveil groundbreaking ALS research findings at the upcoming 2025 MDA Clinical and Scientific Conference in Dallas. Join us to learn about innovative studies and treatments.

Mitsubishi Tanabe Pharma America to Present ALS Research at MDA 2025 Conference #USA #Jersey_City #ALS #Mitsubishi_Tanabe_Pharma #RADICAVA_ORS